Cargando…
What Is the Future of Thiazolidinediones (TZDs) After Market Introduction of Inhaled Insulin?
The U.S. Food and Drug Administration (FDA) approved inhaled insulin (INH) under the trade name Exubera on January 27, 2006, for use in adult patients with type 1 and type 2 diabetes. Exubera is an inhalable, powdered form of insulin delivered by a device developed by Nektar Therapeutics. Earlier in...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Academy of Managed Care Pharmacy
2006
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437679/ https://www.ncbi.nlm.nih.gov/pubmed/16515377 http://dx.doi.org/10.18553/jmcp.2006.12.2.169 |
| _version_ | 1785092587101618176 |
|---|---|
| author | Curtiss, Frederic R. |
| author_facet | Curtiss, Frederic R. |
| author_sort | Curtiss, Frederic R. |
| collection | PubMed |
| description | The U.S. Food and Drug Administration (FDA) approved inhaled insulin (INH) under the trade name Exubera on January 27, 2006, for use in adult patients with type 1 and type 2 diabetes. Exubera is an inhalable, powdered form of insulin delivered by a device developed by Nektar Therapeutics. Earlier in January 2006, Pfizer agreed to acquire the world-wide rights to Exubera from sanofi-aventis for $1.3 billion. |
| format | Online Article Text |
| id | pubmed-10437679 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2006 |
| publisher | Academy of Managed Care Pharmacy |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104376792023-08-21 What Is the Future of Thiazolidinediones (TZDs) After Market Introduction of Inhaled Insulin? Curtiss, Frederic R. J Manag Care Pharm Editorials The U.S. Food and Drug Administration (FDA) approved inhaled insulin (INH) under the trade name Exubera on January 27, 2006, for use in adult patients with type 1 and type 2 diabetes. Exubera is an inhalable, powdered form of insulin delivered by a device developed by Nektar Therapeutics. Earlier in January 2006, Pfizer agreed to acquire the world-wide rights to Exubera from sanofi-aventis for $1.3 billion. Academy of Managed Care Pharmacy 2006-03 /pmc/articles/PMC10437679/ /pubmed/16515377 http://dx.doi.org/10.18553/jmcp.2006.12.2.169 Text en Copyright © 2006, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited. |
| spellingShingle | Editorials Curtiss, Frederic R. What Is the Future of Thiazolidinediones (TZDs) After Market Introduction of Inhaled Insulin? |
| title | What Is the Future of Thiazolidinediones (TZDs) After Market Introduction of Inhaled Insulin? |
| title_full | What Is the Future of Thiazolidinediones (TZDs) After Market Introduction of Inhaled Insulin? |
| title_fullStr | What Is the Future of Thiazolidinediones (TZDs) After Market Introduction of Inhaled Insulin? |
| title_full_unstemmed | What Is the Future of Thiazolidinediones (TZDs) After Market Introduction of Inhaled Insulin? |
| title_short | What Is the Future of Thiazolidinediones (TZDs) After Market Introduction of Inhaled Insulin? |
| title_sort | what is the future of thiazolidinediones (tzds) after market introduction of inhaled insulin? |
| topic | Editorials |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437679/ https://www.ncbi.nlm.nih.gov/pubmed/16515377 http://dx.doi.org/10.18553/jmcp.2006.12.2.169 |
| work_keys_str_mv | AT curtissfredericr whatisthefutureofthiazolidinedionestzdsaftermarketintroductionofinhaledinsulin |